Comprehensive information about experimentally validated enhancers
| Enhancer ID: | E_01320 |
| Species: | Homo sapiens |
| Position : | chr3:46453226-46459225 |
| Year: | 2025 |
| Title: | Enhancer transcription profiling reveals an enhancer RNA-driven ferroptosis and new therapeutic opportunities in prostate cancer |
| Genome Build: | hg38 |
| Enhancer Type: | Enhancer |
| Condition: | Disease |
| Disease Name: | prostate cancer |
| PMID: | 40082405 |
| MONDO: | MONDO:0008315 |
| Tissue: | Prostate |
| Tissue Ontology ID: | UBERON:0002367 |
| Cell Source: | LNCaP |
| CVCL ID: | CVCL_0395 |
| Cell Type: | prostate carcinoma cell |
| Cell Ontology ID: | CL:0000066 |
| Experiment Type: | Functional perturbation assay, Enhancer activity assay, Chromatin interaction assay, TF binding assay |
| High Throughput Method: | ATAC-seq, RNA-seq, ChIP-seq, 3C-seq |
| Low Throughput Method: | Luciferase Reporter Assay, ChIP-RT-qPCR, RT-RT-qPCR, Western blot, FISH |
| Target gene : | LTF |
| TF name : | HNRNPF; AR |
| Regulatory State : | Active |
| GeneName | Pathway Name | Source | Gene Number |
|---|